Code
MOG-LCFP-03AX
Test
Active-Compendium
81449
81449
Clinical
Oncology,Pathology
FFPE tissue: Paraffin block is preferred. Alternatively, send 1 H&E slide plus 5-10 unstained slides cut at 5 or more microns. Please use positively-charged slides and 10% NBF fixative. Do not use zinc fixatives.
Flag Active
True
Orderable Test Description
<p>The Lung NGS Fusion Panel (Complete or Limited) is an RNA-based next-generation sequencing panel that detects translocations and fusions of the genes ALK, MET including MET Exon 14 skipping, NTRK1, NTRK2, NTRK3, NRG1, RET and ROS1 with known and novel fusion partners. Examples of some of the published fusions detectable in this test include EML4-ALK, KIF5B-ALK, NPM1-ALK, CD74-NTRK1, MPRIP-NTRK1, TPM3-NTRK1, TRIM24-NTRK2, PAN3-NTRK2, ETV6-NTRK3, CCD6-RET (aka RET-PTC1), KIF5B-RET, NCOA4-RET (aka RET-PTC3), CD74-ROS1, SLC34A2-ROS1, and TPM3-ROS1. Lung Complete NGS Fusion Panel includes all genes listed above. Clients can opt out of ALK and ROS1 testing to receive the Lung Limited NGS Fusion Panel report. This test may be used to select patients for the following FDA-approved therapies: ALK- ALECENSA® (alectinib), XALKORI® (crizotinib), ZYKADIA (ceritinib), ALUNBRIG® (brigatinib), LORBRENA® (lorlatinib) MET Exon 14- TABRECTA (capmatinib) NTRK- ROZLYTREK® (entrectinib), VITRAKVI® (larotrectinib) RET- GAVRETO (pralsetinib), RETEVMO (selpercatinib) ROS- XALKORI® (crizotinib), ROZLYTREK® (entrectinib)</p>
Orderable Turn Around Time
21 Days
Keywords
Extra Note
Use cold pack for transport, making sure cold pack is not in direct contact with specimen. NYS clients please provide date and time of Collection.
NY Approved
True
Orderable Biomarkers JSON
{"RNA Sequencing": {"Fusions": ["NTRK1", "MET", "NTRK2", "NTRK3", "ROS1", "ALK", "NRG1", "RET"], "Splice Variant": ["MET exon 14 Skipping"]}}
Keywords string
Larotrectinib, Vitrakvi, NGSfusionsearch Lung NGS Fusion Panel (Complete or Limited)
Title URL
lung-ngs-fusion-panel-complete-or-limited